Lexaria Bioscience Income Statement

Financials in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '25 Nov 30, 2025	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Revenue	0.52	0.71	0.46	0.23	0.26	0.72
Revenue Growth (YoY)	5.05%	52.05%	105.24%	-11.43%	-64.66%	129.59%
Cost of Revenue	-	0	0	0.03	0.07	0.18
Gross Profit	0.52	0.7	0.46	0.19	0.18	0.55
Selling, General & Admin	4.08	4.1	3.79	2.96	4.96	4.97
Research & Development	6.96	8.24	2.36	3.67	1.84	1.26
Operating Expenses	11.04	12.34	6.15	6.62	6.8	6.23
Operating Income	-10.52	-11.63	-5.7	-6.43	-6.62	-5.69
Interest & Investment Income	0	0	0.01	0.04	-	-
EBT Excluding Unusual Items	-10.51	-11.63	-5.68	-6.38	-6.62	-5.69
Gain (Loss) on Sale of Investments	-0.04	-0.03	-0.07	-0.22	-0.76	-
Asset Writedown	-0.25	-0.25	-0.06	-0.11	-	-
Pretax Income	-10.8	-11.91	-5.81	-6.71	-7.38	-5.69
Earnings From Continuing Operations	-10.8	-11.91	-5.81	-6.71	-7.38	-5.69
Earnings From Discontinued Operations	-	-	-	-	-	1.5
Net Income to Company	-10.8	-11.91	-5.81	-6.71	-7.38	-4.19
Minority Interest in Earnings	0.01	0.01	0.01	0.05	0.11	0.16
Net Income	-10.79	-11.9	-5.8	-6.66	-7.27	-4.03
Net Income to Common	-10.79	-11.9	-5.8	-6.66	-7.27	-4.03
Shares Outstanding (Basic)	19	18	12	7	6	4
Shares Outstanding (Diluted)	19	18	12	7	6	4
Shares Change (YoY)	34.21%	45.34%	87.24%	12.38%	34.02%	58.34%
EPS (Basic)	-0.56	-0.66	-0.47	-1.01	-1.24	-0.92
EPS (Diluted)	-0.56	-0.66	-0.47	-1.01	-1.24	-0.92
Free Cash Flow	-8.71	-10.48	-5	-5.91	-4.93	-3.99
Free Cash Flow Per Share	-0.45	-0.58	-0.40	-0.89	-0.84	-0.91
Gross Margin	100.00%	99.61%	98.96%	86.08%	71.87%	75.74%
Operating Margin	-2014.62%	-1647.97%	-1226.70%	-2841.31%	-2591.67%	-786.85%
Profit Margin	-2067.65%	-1686.00%	-1248.25%	-2946.36%	-2846.28%	-557.19%
Free Cash Flow Margin	-1668.28%	-1483.88%	-1077.38%	-2614.84%	-1929.75%	-552.02%
EBITDA	-10.44	-11.55	-5.62	-6.28	-6.52	-5.58
D&A For EBITDA	0.07	0.09	0.08	0.15	0.1	0.11
EBIT	-10.52	-11.63	-5.7	-6.43	-6.62	-5.69

Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q